Loading
SPT-300 / Major Depressive Disorder With Anxious Distress / Major Depressive Disorder (MDD) · Phase 2 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2, randomized, placebo-controlled trial of SPT-300 for major depressive disorder that is currently recruiting. No efficacy or safety results have been posted to the registry, and the study design and primary endpoints are reported in the registration record only.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress; age from 18 Years; to 65 Years. Intervention: SPT-300. Compared with: Placebo — Placebo Comparator. n = 360. 62 sites across 7 countries.
This is a Phase 2, randomized, placebo-controlled trial of SPT-300 for major depressive disorder that is currently recruiting. No efficacy or safety results have been posted to the registry, and the study design and primary endpoints are reported in the registration record only.
This is a registry record; no efficacy or safety results are reported.
The source did not state who this applies to in practice.
This is a Phase 2 trial registration with no reported results; the study is actively recruiting and outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07065240). This is a study registration, not published results. Lead sponsor: Seaport Therapeutics. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 360 participants (ESTIMATED). Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress. Interventions: DRUG: SPT-300; DRUG: Placebo. Primary outcome measures: Change From Baseline to Day 42 in Hamilton Depression Rating Scale-17 (HAM-D-17) Total Score , Baseline (Day 0) to Day 42. Brief summary: This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.